E Fund Management Co. Ltd. Has $91,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

E Fund Management Co. Ltd. cut its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 60.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,071 shares of the company’s stock after selling 17,057 shares during the period. E Fund Management Co. Ltd.’s holdings in Travere Therapeutics were worth $91,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in TVTX. EntryPoint Capital LLC acquired a new stake in Travere Therapeutics in the first quarter valued at approximately $32,000. Quest Partners LLC grew its position in Travere Therapeutics by 240.6% in the 2nd quarter. Quest Partners LLC now owns 14,336 shares of the company’s stock valued at $118,000 after purchasing an additional 10,127 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Travere Therapeutics by 68.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock valued at $113,000 after purchasing an additional 5,962 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Travere Therapeutics during the fourth quarter worth $137,000. Finally, SG Americas Securities LLC bought a new position in shares of Travere Therapeutics in the second quarter valued at $139,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TVTX shares. Bank of America upped their target price on shares of Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Guggenheim upgraded Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a report on Monday, September 9th. Wedbush raised their price objective on Travere Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Barclays increased their target price on shares of Travere Therapeutics from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average price target of $17.58.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $15.06 on Friday. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $15.23. The firm’s 50-day simple moving average is $9.99 and its two-hundred day simple moving average is $8.13.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. The company had revenue of $54.12 million during the quarter, compared to the consensus estimate of $49.50 million. On average, equities research analysts forecast that Travere Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Insider Buying and Selling at Travere Therapeutics

In other news, SVP William E. Rote sold 4,387 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $50,538.24. Following the completion of the transaction, the senior vice president now owns 84,455 shares in the company, valued at approximately $972,921.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Travere Therapeutics news, CFO Christopher R. Cline sold 2,490 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $28,684.80. Following the sale, the chief financial officer now owns 74,595 shares of the company’s stock, valued at approximately $859,334.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP William E. Rote sold 4,387 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares in the company, valued at approximately $972,921.60. The disclosure for this sale can be found here. Insiders have sold a total of 30,707 shares of company stock worth $352,712 over the last ninety days. 3.75% of the stock is currently owned by company insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.